4448-83-3

Basic information

• Product Name: 2-cycloheptylideneethanol
• CAS NO: 4448-83-3
• Molecular Formula: C₉H₁₆O
• Molecular Weight: 140.2227
• Mol File: 4448-83-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 216.6°C at 760 mmHg
• Flash Point: 94.4°C
• Density: 1.009g/cm³
• Vapor Pressure: 0.0299mmHg at 25°C
• Refractive Index: 1.556
• CAS DataBase Reference: 2-cycloheptylideneethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cycloheptylideneethanol(4448-83-3)
• EPA Substance Registry System: 2-cycloheptylideneethanol(4448-83-3)

Safety Data

• Hazardous Substances Data: 4448-83-3(Hazardous Substances Data)

Upstream product

• 1903-29-3 cycloheptylideneacetic acid 
• 92984-49-1 cycloheptyliden-acetic acid methyl ester 
• 1903-23-7 ethyl cycloheptylideneacetate 
• 502-42-1 cycloheptanone 
• 4480-98-2 2-cycloheptylethanol 

Downstream Products

• 84653-59-8 2',4',6'-trihydroxy-3'-(2-cycloheptylidene-ethyl)isovalerophenone 
• 93796-27-1 5,7-dihydroxy-6-isovalerylchroman-2-spirocycloheptane 
• 93796-25-9 3',5'-bis(cycloheptylidenemethyl)-2',4',6'-trihydroxyisovalerophenone 
• 93796-28-2 3-(2-cycloheptylidene-ethyl)-5,7-dihydroxy-6-isovalerylchroman-2-spirocycloheptane 
• 93796-26-0 4,6-bis(2-cycloheptylidene-ethyl)-3,5,6-trihydroxy-2-isovalerylcyclohexa-1,4-dien-1-one 
• 1393361-31-3 3-(cycloheptylidenemethyl)but-3-en-2-yl benzoate 
• 1443054-72-5 (3R,4R)-3-cycloheptenyl-1-tosylpiperidine-4-carbaldehyde 
• 1443054-38-3 N-(2-cycloheptylideneethyl)-N-(4-hydroxybutyl)-4-methylbenzenesulfonamide 
• 1443054-39-4 N-(2-cycloheptylideneethyl)-4-methyl-N-(4-oxobutyl)benzenesulfonamide 

Relevant articles and documents

Chiral 1,2,3-Triazolium Salt Catalyzed Asymmetric Mono- and Dialkylation of 2,5-Diketopiperazines with the Construction of Tetrasubstituted Carbon Centers

Novel asymmetric mono- and dialkylation reactions of α-substituted 2,5-diketopiperazines catalyzed by new chiral spirocyclic-amide-derived triazolium organocatalysts have been developed, resulting in a range of enantioenriched 2,5-diketopiperazine derivatives containing one or two tetrasubstituted carbon stereocenters. The reactions feature high yields (up to 98%), and excellent cis-diastereo- and enantioselectivities (up to >20:1 dr, >99 % ee), and they provide a new asymmetric synthetic approach to important functionalized 2,5-diketopiperazine skeletons. Furthermore, a possible reaction mechanism was proposed based on both control experiments and extensive DFT calculations.

Copper-Catalyzed Enantio-, Diastereo-, and Regioselective [2,3]-Rearrangements of Iodonium Ylides

The first highly enantioselective, diastereoselective, and regioselective [2,3]-rearrangement of iodonium ylides has been developed as a general solution to catalytic onium ylide rearrangements. In the presence of a chiral copper catalyst, substituted allylic iodides couple with α-diazoesters to generate metal-coordinated iodonium ylides, which undergo [2,3]-rearrangements with high selectivities (up to >95:5 r.r., up to >95:5 d.r., and up to 97 % ee). The enantioenriched iodoester products can be converted stereospecifically into a variety of onium ylide rearrangement products, as well as compounds that are not accessible by classical onium ylide rearrangements.

The synthesis of α,α-disubstituted α-amino acids via ichikawa rearrangement

An approach to α,α-disubstituted α-amino acids is reported. The key step is allyl cyanate-to-isocyanate rearrangement. As demonstrated, the resultant allyl isocyanates can be directly trapped with various nucleophiles, for instance, alcohols, amines, and organometallic reagents, to provide a broad range of N-functionalized allylamines. The developed method has been successfully applied in the synthesis of two bioactive peptides: 2-aminoadamantane-2-carboxylic acid derived P2X7-evoked glutamate release inhibitor and 4-amino-tetrahydropyranyl-4-carboxylic acid derived dipeptide GSK-2793660, which is currently in clinical trials as cathepsin C inhibitor for the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis.